Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 5OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 229fludarabine phosphate 206fludarabine 163Busulfan 150Mycophenolic Acid 135Tacrolimus 133Whole-Body Irradiation 132Peripheral Blood Stem Cell Transplantation 121Cytarabine 101Azacitidine 100Antilymphocyte Serum 98Melphalan 96Cyclosporine 96Methotrexate 87Imatinib Mesylate 87Filgrastim 85Decitabine 66Granulocyte Colony-Stimulating Factor 60Thiotepa 57venetoclax 53Stem Cell Transplantation 53thymoglobulin 51Radiotherapy 49Cord Blood Stem Cell Transplantation 42nilotinib 40Clofarabine 38Dasatinib 37Methylprednisolone 36ruxolitinib 35Etoposide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Nuclear Medicine Department, Hospital × Myeloid × Clear all
NCT06287944 2026-05-18

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1 Recruiting
15 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡